Saturday, October 3, 2026

The AI Psych Brief

🔬 Section 1

Psychiatric Research Article

Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis

Louie K, Jauhar S, Rubio J, Brand B, Pillinger T, Howes OD, McCutcheon RA · The Lancet Psychiatry · August 2026 (online); October 2026 issue

Rapid relapse after stopping an antipsychotic is often read as a pharmacological rebound (dopamine supersensitivity or withdrawal) rather than a return of the underlying illness. The authors pooled individual participant data from five double-blind, placebo-controlled paliperidone discontinuation trials (oral and long-acting injectable) and used latent class mixed modelling on PANSS trajectories of the 417 participants who relapsed.

Two patterns emerged: a rapid-onset and a delayed-onset relapse, with rapid relapsers more severely ill at the point of relapse. Crucially, rapid relapse was not over-represented in the discontinuation arms (LAI 20% vs 11% with continued treatment, p=0.12; oral 27% vs 26%), and symptom profiles at relapse did not differ by whether drug was stopped. What did predict rapid relapse was higher baseline PANSS.

💡 Why it matters

In these trials, fast relapse after stopping paliperidone looked more like the patient's own illness severity than a withdrawal effect — so when deprescribing, stratify by severity and front-load monitoring for the sickest patients rather than assuming slow tapering alone prevents early relapse. Note the findings are paliperidone-specific and come from trial populations.

Read the paper → doi:10.1016/S2215-0366(26)00225-7

🩺 Section 2

General Medicine Article

Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials

Dauvilliers Y, Mignot E, Antczak J, Arnulf I, et al.; The First Light and The Radiant Light investigators · New England Journal of Medicine · September 2026

Narcolepsy type 1 is caused by loss of hypothalamic orexin (hypocretin) neurons. Oveporexton (TAK-861) is an oral, orexin receptor 2-selective agonist — mechanistically the mirror image of the orexin antagonists (suvorexant, lemborexant, daridorexant) we prescribe for insomnia. Two 12-week phase 3 RCTs (First Light, n=168; Radiant Light, n=105) randomized patients aged 16–70 to twice-daily oveporexton 1 or 2 mg or placebo.

On the Maintenance of Wakefulness Test, mean sleep latency improved by 14.3–19.8 minutes versus essentially no change on placebo; Epworth scores fell by roughly 10–12 points (into the normal range for many), and median weekly cataplexy fell by 79–89% versus 28–39% on placebo. Adverse events were frequent (86–89% vs 43–54%), mainly urinary frequency and transient insomnia.

💡 Why it matters

Narcolepsy is a classic psychiatric mimic — hypnagogic hallucinations get labelled psychosis, and sleepiness gets labelled depression or stimulant-seeking — so a first-in-class orexin agonist that restores near-normal wakefulness raises the stakes of asking about cataplexy and sleep paralysis before diagnosing. It also makes orexin a two-directional drug target psychiatrists will increasingly meet.

Read the paper → doi:10.1056/NEJMoa2601598

💊 Section 3

Psychiatric Fact

Clozapine myocarditis runs on a calendar — and CRP warns you first

Clozapine-induced myocarditis is overwhelmingly an early event: most cases present in the first four weeks, clustering around days 14–21, and it is rare after two months. That timing is why the widely used Ronaldson monitoring protocol asks for baseline troponin and CRP, then weekly levels through week 4, rather than relying on symptoms — early myocarditis often looks like a viral illness (fever, tachycardia, malaise) that residents are tempted to attribute to benign clozapine fever. CRP typically rises a few days before troponin, so a CRP above roughly 100 mg/L or a troponin more than twice the upper limit should stop clozapine; a CRP of 50–100 mg/L warrants daily troponin and CRP until the trend declares itself. Rapid titration and concurrent valproate have been associated with higher risk, so slow the schedule in those patients. A resolved episode is not always an absolute bar to rechallenge, but it requires cardiology input and a slower titration.

🛋️ Section 4

Psychotherapy Teaching Pearl

Boredom in the session is a clinical finding, not a mood

Countertransference boredom is easy to dismiss as fatigue or a dull case, but in dynamic work it is often the clinician's experience of a defense — specifically a defense that deadens affect and severs links between one thought and the next. Bion described attacks on linking; Green's 'dead mother' patients recreate an emotionally absent object by keeping the session lifeless. The patient narrates events at a steady, affectless pitch, and the therapist's mind drifts because there is nothing alive to attach to. Treating boredom as data shifts the question from 'why is this patient boring?' to 'what is being kept out of the room, and what would happen if it came in?' The technical move is to comment on the process — the flatness itself — tentatively and in the here-and-now, not to interpret the content being recited or to inject energy by asking more questions.

🗒️ Vignette

A 35-year-old accountant spends the fourth consecutive session detailing a spreadsheet dispute with a coworker in the same even tone. The resident notices she has reread the clock twice and feels faintly guilty. Instead of asking another question about the coworker, she says: "I notice you're describing something that sounds maddening, but it comes out very level — almost as if the feeling has been filed away. I wonder what it would be like if it were in the room with us." After a pause the patient says, "My mother used to leave the room when I got upset." The resident's boredom was the invitation to play the absent mother; naming the flattening, rather than enacting withdrawal, lets the affect return.